ArticleBMC cancer2022

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.

Yukinori Ozaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.